Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product (Oncolytic Viral Therapies & Cancer Vaccines, Monoclonal Antibodies, Immunomodulators), By Cancer Type (Breast, Lung), and Segment Forecasts, 2019 - 2026

Report Overview

The global cancer immunotherapy market size was valued at USD 58.1 Billion in 2018. Growing adoption of advanced cancer therapeutic options coupled with rising cancer incidence has been one of the primary growth stimulants for the market. Healthcare providers are focusing on improving cancer therapeutic facilities and a reduction in the recurrence rate of tumor post chemotherapy.

Rising R&D activities in the cancer immunotherapy field is resulting in the introduction of advanced variants with enhanced efficacy and effectiveness of treatment. Immuno-oncology have shown promising results with improved survival and lower toxicity. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.

Immunotherapies in the pipeline are likely to provide more treatment choices and better outcomes than existing therapies. Introduction of newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to target receptors related to multiple myeloma, is poised to shape the future of the market. Ongoing studies on similar drugs intended to minimize adverse effects are projected to spur the growth of the market.

In addition, approval of PD-1 and CTLA-4 checkpoint inhibitors for melanoma and Non-Small Cell Lung Cancer (NSCLC) has been boosting the growth of the market. Approval of innovative immunotherapy drug forms, such as vaccines and adjuvants, is on a rise. Moreover, more immunotherapies are being tested for enhanced outputs, such as immunomodulators and CAR T-cell therapy. These new approvals and ongoing research are anticipated to stimulate the growth of the market over the forecast period.

Product Insights

Monoclonal antibodies (mAbs) were the most prominent product segment in 2018. Increasing investments in R&D of monoclonal antibodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened new avenues of revenue generation for companies that provide oncology therapeutics. These R&D activities are resulting in introduction of mAbs that have effects such as adaptive immunity, antigen specificity, and antibody dependent cellular toxicity. Owing to several benefits of mAbs, they are being studied for treatment of various types of tumors.

Immunomodulators, unlike other chemo-immunotherapy drugs, are used to modulate immune system of patients, which in turn, enhance the activity of immune system against tumors. Immunomodulators such as cytokine modulators and growth factors are nonspecific therapies. These nonspecific therapies are designed to act as immune stimulating agents leading to improved responses against tumor cells. 

Rising effectivity and accuracy of these immunomodulatory drugs are resulting in their increased market penetration. Along with these approved drugs, market players are working towards introducing several novel therapies.

Cancer Type Insights

By type, the global cancer immunotherapy market has been segmented into lung, breast, colorectal, melanoma, prostate, head & neck, ovarian, and pancreatic cancer. Majority of immunotherapy drugs including few monoclonal antibodies and checkpoint inhibitors are approved for treatment of NSCLC. Monoclonal antibodies successfully prevent formation of new blood vessels by tumor cells, thus facilitating inhibition of an alternative path for growth of tumor cells.

Checkpoint inhibitors are used as a first-line treatment in patients suffering from advanced lung tumor. Opdivo, Keytruda, and Tecentriq are immunotherapeutic drugs approved for lung tumor. These drugs are usually prescribed in cases of recurrence of tumor post chemotherapy. The aforementioned factors are estimated to bolster the adoption of these drugs.

Cancer immunotherapies are being increasingly used for melanoma therapeutics. The growth of the melanoma segment can be attributed to development of new products, large number of FDA approvals, and extensive R&D in this field. The U.S. FDA has recently approved three checkpoint inhibitors for melanoma treatment, three cytokine therapies, and one oncolytic virus therapy. Keytruda, Yervoy, and Opdivo are commercially available checkpoint inhibitors, which boost patient’s immune response against melanoma cells, thus shrinking tumors and increasing the lifespan of patients suffering from advanced melanoma.

Regional Insights

North America held the largest revenue share in 2018. Rising incidence of the disease, increasing ease of access to modern therapeutics, coupled with expanding geriatric population, are contributing to the growth of the regional market.

Asia Pacific is expected to experience the fastest growth during the forecast period. New and advanced immunotherapy drugs are being introduced in China and Japan. These countries have several ongoing clinical trials as well as FDA approvals for new drug molecules and combination therapies. Approval of new treatment drugs in China and Japan are boosting the adoption of immunotherapy for treatment of tumors. Moreover, lack of regulatory & cultural inhibitions and presence of market players with major investments in the market, such as AstraZeneca; Merck & Co., Inc.; and Pfizer, Inc., are augmenting the Asia Pacific market.

Key Companies & Market Share Insights

The market is highly competitive in nature. Key participants include Amgen Inc.; AstraZeneca; F. Hoffman La Roche; Bayer AG; Bristol-Myers Squibb; Eli Lilly and Co.; Merck and Co.; Novartis; and Pfizer.

Key parameters affecting competitive nature are rapid adoption of advanced treatment options for improved healthcare coupled with rising need for optimum capital utilization. In addition, in an attempt to retain share and diversify product portfolio, major players are frequently adopting mergers & acquisition strategies.

Cancer Immunotherapy Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global cancer immunotherapy market report based on product, cancer type, and region:

• Product Outlook (Revenue, USD Billion, 2015 - 2026)

  • Monoclonal Antibodies

  • Immunomodulators

  • Oncolytic Viral Therapies and Cancer Vaccines

• Cancer Type Outlook (Revenue, USD Billion, 2015 - 2026)

  • Lung Cancer

  • Breast Cancer

  • Colorectal Cancer

  • Melanoma

  • Prostate Cancer

  • Head and Neck Cancer

  • Ovarian Cancer

  • Pancreatic Cancer

• Regional Outlook (Revenue, USD Billion, 2015 - 2026)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • India

    • China

    • Japan

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • U.A.E.